Your Daily Pharma Scoop: Intra-Cellular Therapies Completes Rolling NDA, Amarin Rallies Further, Insmed's Approval [Seeking Alpha]
Insmed Incorporated (INSM)
Last insmed incorporated earnings: 4/30 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.insmed.com
Company Research
Source: Seeking Alpha
Summary Welcome to the Daily Pharma Scoop, a daily feature from the creators of the Total Pharma Tracker, a popular biopharma Marketplace service here on Seeking Alpha. In the daily scoop, we focus in on one key investment concept from the biopharma space and also provide quick commentary on other important news and a set of selected links to major news from the day before. Intra-Cellular Therapies completes rolling NDA We recently covered Intra-Cellular Therapies ( ITCI ) on Seeking Alpha. On Friday, the company completed the rolling submission of its NDA for lumateperone for the treatment of schizophrenia. Given 3 months for acceptance and another 6 for PDUFA date (the drug is Fast Tracked for the indication), we expect a PDUFA date of no later than July 2019. The NDA is backed by 20 clinical trials and data from more than 1900 subjects who have taken lumateperone. As we said in our coverage, what differentiates lumateperone is that, besides its demonstrated efficacy
Show less
Read more
Impact Snapshot
Event Time:
INSM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INSM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INSM alerts
High impacting Insmed Incorporated news events
Weekly update
A roundup of the hottest topics
INSM
News
- Insmed Incorporated (NASDAQ: INSM) had its price target raised by analysts at Barclays PLC from $37.00 to $40.00. They now have an "overweight" rating on the stock.MarketBeat
- What Makes Insmed (INSM) a Lucrative Investment? [Yahoo! Finance]Yahoo! Finance
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)PR Newswire
- Insmed Incorporated (NASDAQ: INSM) had its "overweight" rating re-affirmed by analysts at Wells Fargo & Company. They now have a $55.00 price target on the stock.MarketBeat
- Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference [Yahoo! Finance]Yahoo! Finance
INSM
Earnings
- 2/22/24 - Miss
INSM
Sec Filings
- 4/1/24 - Form DEFA14A
- 4/1/24 - Form DEF
- 3/11/24 - Form 8-K
- INSM's page on the SEC website